SLS SELLAS Life Sciences Group, Inc. - Common Stock
SELLAS Life Sciences Group, Inc. - Common Stock के बारे में विकिपीडिया से कंपनी का अवलोकन
Galena Biopharma, Inc. was a publicly traded pharmaceutical company based in San Ramon, California. The company was founded in Worcester, Massachusetts. In 2011, it moved to Oregon, and in 2015 moved to San Ramon, California. Mark Schwartz was the company's president and chief executive officer. As of December 29, 2017, the company was acquired by Sellas Life Sciences Group Ltd. through a reverse merger transaction. Galena Biopharma was renamed to Sellas Life Sciences Group, Inc..
और पढ़ें
Galena Biopharma, Inc. (originally RXi Pharmaceuticals) was a publicly traded pharmaceutical company based in San Ramon, California. The company was founded in Worcester, Massachusetts. In 2011, it moved to Oregon, and in 2015 moved to San Ramon, California. Mark Schwartz was the company's president and chief executive officer. As of December 29, 2017, the company was acquired by Sellas Life Sciences Group Ltd. through a reverse merger transaction. Galena Biopharma was renamed to Sellas Life Sciences Group, Inc. (Nasdaq: SLS).
History
In November 2006, Argonaut Pharmaceuticals, Inc. changed the name to RXi Pharmaceuticals Corporation. RXi was a subsidiary of CytRx Corp., which provided $15 million in financing in April 2007. RXi was founded in part by Nobel Prize winner Craig Mello. In September 2007, RXi signed a licensing deal with TriLink Biotechnologies, a competitor in the RNA interference (RNAi) field, in which RXi would pay TriLink to use three of TriLink's technologies.
In March 2011, the company announced the planned acquisition of Arizona-based Apthera, Inc. for $7 million. The acquisition included the breast cancer drug NeuVax. In June 2011, NeuVax was approved by the United States Food and Drug Administration to start a stage three clinical trial.
In September 2011, the company separated its cancer therapies division. It was renamed Galena Biopharma Inc and moved to Lake Oswego, Oregon. RXi became a subsidiary of Galena and retained RNAi technologies. RXi Pharmaceuticals remained in Massachusetts as a publicly traded company. In January 2014, Galena bought Mills Pharmaceuticals. In April 2014, the company headquarters moved to Portland.
In November 2011, the company partnered with Genentech to combine drugs from each company for a cancer treatment. Galena is currently studying the combination of NeuVax and Herceptin in phase II trials.
Leadership
In March 2011, president and CEO Noah Beerman were replaced by Mark Ahn, and in August 2014, Ahn resigned and was replaced by Mark Schwartz. On January 31, 2017, Galena announced the resignation of Mark Schwartz effective that day, and reported in the same press release that it would be exploring strategic alternatives to maximize shareholder value going forward.
Stock
RXi went public in March 2008. CytRx retained 49% ownership of RXi's stock and gave shares of RXi to existing shareholders. Trading began on the Nasdaq market on March 12, 2008, under the ticker symbol of RXII. Fidelity Investments invested $8.5 million in the company in May 2008, followed by a $25 million private-equity investment by Yorkville in February 2009. In 2010, RXi received a National Institutes of Health grant of $600,000. By August 2010, the company had 30 employees. In April 2011, RXi raised about $12 million from a stock offering and received $580,000 in grants from the National Institutes of Health. The company reported a loss of $11.5 million loss for 2011.
In November 2012, an anonymous internet report caused Galena stock to decline. The company filed a lawsuit claiming the report was false and attempted to manipulate the stock. In 2014, Galena's involvement in a fraudulent stock promotion scheme was exposed. On February 1, 2014, analyst Matt Gravitt published an article that revealed Galena had paid MissionIR, DreamTeam brand, to promote Galena's stock. Galena's stock fell 20% following this revelation that received a heated response, and was one of the three most read articles in Seeking Alpha's history. Over the next few weeks, more revelations came out and the company admitted their stock promotion relationship and insider selling. Galena then disclosed that the SEC was investigation their relationship with The DreamTeam Group. By March 2014, five lawsuits were filed against Galena and several of its officers alleging that the company used misleading articles to boost stock prices. Motley Fool, discussing the 23% stock price drop during March 2015, noted there was stock dilution from the offering and also that Abstral's sales were below Galena's estimates from late 2013. Discussing the Motley Fool article, Portland Business Journal also noted the ongoing insider-trading lawsuits as a factor in the stock price. A few days later, Zacks Investment Research said Galena could be a "great candidate" to beat its earnings. In response, Galena's CEO said there were many positive aspects to the company, and that the lawsuits weren't a worry as they should get covered under Directors and officers liability insurance. The company moved to San Ramon, California, in the Bay Area in 2015.
Stock promotion scandal
The revelation that Galena was engaging in fraudulent stock promotion without adequate disclosure led to the investigation of other biotech companies who engaged in similar activities. Richard Pearson, an investor who went undercover to investigate the stock promotion firms, wrote an exposé on DreamTeam and its ties to articles about Galena, CytRx, and other companies on media websites. In April 2017, the Securities and Exchange Commission announced enforcement actions against 27 individuals and entities behind various alleged stock promotion schemes. Fraud charges were filed against three public companies, seven stock promotion or communications firms, and two company CEOs; also on this hit list are six individuals and nine writers.
Merger with Sellas Life Sciences
In 2017, Galena Biopharma Inc. announced a merger "with privately-held oncology company Sellas Life Sciences Group Ltd. in an all-stock transaction." The combined company was Sellas Life Science Group. The newly merged companies focused on the development of novel treatments for cancer.
Products
Galena acquired the experimental breast cancer drug NeuVax in 2011 and are currently in phase II trials to combine the drug with Genentech's Herceptin.
In 2013, Galena began selling its first developed drug, an analgesic for cancer pain named Abstral Sublingual.
Anagrelide controlled-released (GALE-401) was approved by the FDA for phase III clinical trials for the treatment of essential thrombocytosis in December 2016.
GALE-301 and GALE-302 are immunotherapies in phase I and II trials for ovarian and breast cancers.
== References ==
स्रोत: विकिपीडिया (अंग्रेज़ी), CC BY-SA 4.0 · विकिपीडिया पर देखें ↗
SLS स्टॉक स्नैपशॉट मूल्य, बाजार पूंजीकरण, P/E, EPS, ROE, ऋण/इक्विटी, 52-सप्ताह की सीमा
SLS स्टॉक मूल्य चार्ट तकनीकी संकेतकों के साथ दैनिक OHLCV — पैन, ज़ूम और अपना दृश्य कस्टमाइज़ करें
10-वर्षीय प्रदर्शन राजस्व, शुद्ध आय, मार्जिन और ईपीएस रुझान
मूल्यांकन P/E, P/S, P/B, EV/EBITDA अनुपात — क्या स्टॉक महंगा है या सस्ता?
लाभप्रदता सकल, परिचालन और शुद्ध मार्जिन; ROE, ROA, ROIC
वित्तीय स्वास्थ्य ऋण, तरलता, शोधन क्षमता — बैलेंस शीट की मजबूती
विकास राजस्व, EPS और शुद्ध आय वृद्धि: YoY, 3Y CAGR, 5Y CAGR
पूंजी दक्षता एसेट टर्नओवर, इन्वेंटरी टर्नओवर, प्राप्य टर्नओवर
SLS विश्लेषक सर्वसम्मति तेजी और मंदी के विश्लेषक राय, 12-महीने का मूल्य लक्ष्य, अपसाइड
- मजबूत खरीद 1 16.7%
- खरीदें 4 66.7%
- होल्ड 1 16.7%
- बेचें 0 0.0%
- मजबूत बिक्री 0 0.0%
12-महीने का मूल्य लक्ष्य
2 विश्लेषक · 2026-08-14Earnings History EPS वास्तविक बनाम अनुमान, आश्चर्य %, बीट दर, अगली आय तिथि
| Period | EPS Actual | EPS अनुमान | आश्चर्य |
|---|---|---|---|
| 31 मार्च 2026 | $-0.05 | $-0.04 | -0.01% |
| 31 दिसमबर 2025 | $-0.05 | $-0.07 | 0.02% |
| 30 सितमबर 2025 | $-0.06 | $-0.07 | 0.01% |
| 30 जून 2025 | $-0.07 | $-0.08 | 0.01% |
| 31 मार्च 2025 | $-0.07 | $-0.11 | 0.04% |
| 31 दिसमबर 2024 | $-0.08 | $-0.11 | 0.03% |
सहकर्मी तुलना (GICS उप-उद्योग) प्रमुख मेट्रिक्स बनाम सेक्टर के साथी
| टिकर | मार्केट कैप | P/E | राजस्व YoY | शुद्ध मार्जिन | ROE | सकल मार्जिन |
|---|---|---|---|---|---|---|
| SLS | $577M | -15.1 | — | — | -55.4% | — |
| IRON | $3.01B | -13.2 | — | — | -31.3% | — |
| BEAM | $2.82B | -34.2 | 120.0% | -57.2% | -7.0% | — |
| NRIX | $1.80B | -5.8 | 53.9% | -314.9% | -53.6% | — |
| RARE | $2.22B | -3.9 | 20.2% | -85.4% | -1613.2% | — |
| KOD | $1.73B | -6.5 | — | — | -202.0% | — |
| BCRX | $1.66B | 6.4 | 94.1% | 30.2% | -97.6% | — |
| PGEN | $1.48B | -3.1 | 146.7% | -2588.2% | 3159.1% | — |
| CDNA | $959M | -47.1 | 13.8% | -5.6% | -6.8% | — |
| COAG | — | — | — | — | — | — |
पूर्ण मौलिक सभी मेट्रिक्स प्रति वर्ष — आय विवरण, बैलेंस शीट, नकदी प्रवाह
आय विवरण 15
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | $0 | $1M | $8M | $2M | $0 | · | · | · | · | $9M | |
| Cost of Revenue | $0 | $0 | $0 | $100.0K | $200.0K | $0 | · | · | · | · | · | $1M | |
| R&D Expense | · | · | · | · | $16M | $9M | $7M | $9M | $6M | $11M | · | · | |
| SG&A Expense | $12M | $12M | $14M | $13M | $11M | $10M | $10M | $13M | $15M | $5M | · | · | |
| Operating Expenses | $28M | $32M | $38M | $43M | $33M | $19M | $20M | $31M | $23M | $32M | $34M | $44M | |
| Operating Income | $-28M | $-32M | $-38M | $-42M | $-25M | $-17M | $-20M | · | $-23M | $-16M | $-34M | $-44M | |
| Other Non-op | $1M | $632.0K | $529.0K | $649.0K | $4M | $208.0K | $-19M | $-29M | $-24M | $5M | $509.0K | $170.0K | |
| Pretax Income | $-27M | $-31M | $-37M | $-41M | $-21M | $-17M | $-19M | $-29M | $-24M | $-18M | $-39M | $-28M | |
| Income Tax | $0 | $0 | $0 | $0 | $-237.0K | $-17.0K | $-81.0K | $-1M | $300.0K | $1.0K | $365.0K | $0 | |
| Net Income | $-27M | $-31M | $-37M | $-41M | $-21M | $-17M | $-19M | $-28M | $-24M | $-18M | $-64M | $-37M | |
| EPS (Basic) | $-0.25 | $-0.50 | $-1.34 | $-2.13 | $-1.34 | $-2.11 | · | · | · | · | · | · | |
| EPS (Diluted) | $-0.25 | $-0.50 | $-1.34 | $-2.13 | $-1.34 | $-2.11 | · | · | · | · | · | · | |
| Shares (Basic) | 109,051,215 | 61,202,412 | 27,777,111 | 19,395,709 | 15,481,113 | 7,977,104 | · | · | · | · | · | · | |
| Shares (Diluted) | 109,051,215 | 61,202,412 | 27,777,111 | 19,395,709 | 15,481,113 | 7,977,104 | · | · | · | · | · | · | |
| EBITDA | $-28M | $-32M | $-38M | $-42M | $-25M | $-17M | · | · | $-23M | $-32M | · | · |
बैलेंस शीट 22
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $72M | $14M | $3M | $17M | $21M | $35M | $7M | $5M | $2M | $6M | $1M | $24M | |
| Receivables | · | · | · | · | $0 | · | · | · | · | · | · | $2M | |
| Inventory | · | · | · | · | · | · | · | · | · | · | $0 | $655.0K | |
| Prepaid Expense | $3M | $2M | $542.0K | $531.0K | $2M | $395.0K | $557.0K | $387.0K | $337.0K | $332.0K | $1M | $1M | |
| Current Assets | $75M | $16M | $3M | $18M | $23M | $37M | $8M | $6M | $13M | $6M | $54M | $52M | |
| PP&E (Net) | · | · | · | · | · | · | · | · | · | $199.0K | $335.0K | $285.0K | |
| Goodwill | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $6M | $6M | $6M | |
| Total Assets | $78M | $19M | $6M | $21M | $26M | $46M | $17M | $17M | $34M | $6M | $82M | $80M | |
| Accounts Payable | $3M | $4M | $6M | $3M | $2M | $5M | $4M | $4M | $12M | $840.0K | $2M | $2M | |
| Accrued Liabilities | $4M | $5M | $8M | $6M | $3M | $2M | $1M | $2M | $3M | $4M | $5M | $9M | |
| Current Liabilities | $7M | $10M | $14M | $16M | $5M | $12M | $5M | $6M | $25M | $6M | $57M | $27M | |
| Capital Leases | $457.0K | $457.0K | $460.0K | $573.0K | $610.0K | $825.0K | $0 | $0 | · | · | · | · | |
| Deferred Tax | · | · | · | · | $0 | $239.0K | $262.0K | $357.0K | $2M | · | · | · | |
| Total Liabilities | $7M | $10M | $14M | $16M | $6M | $18M | $11M | $12M | $31M | $11M | $69M | $43M | |
| Long-term Debt | · | · | · | · | · | · | · | $0 | $11M | · | $5M | $8M | |
| Total Debt | · | · | · | · | · | · | · | · | $11M | $16M | · | · | |
| Common Stock | $15.0K | $7.0K | $3.0K | $2.0K | $2.0K | $1.0K | $1.0K | $1.0K | $1.0K | $2.0K | $15.0K | $12.0K | |
| Retained Earnings | $-275M | $-248M | $-217M | $-180M | $-139M | $-118M | $-101M | $-82M | $-54M | $-30M | · | · | |
| Treasury Stock | · | · | · | · | · | · | · | · | · | $4M | $4M | $4M | |
| Stockholders' Equity | $71M | $9M | $-8M | $5M | $20M | $28M | $6M | $5M | $2M | $-5M | $-12M | $37M | |
| Liabilities + Equity | $78M | $19M | $6M | $21M | $26M | $46M | $17M | $17M | $34M | $6M | $82M | $80M | |
| Shares Outstanding | 153,103,459 | 73,977,459 | 32,132,890 | 21,005,405 | 15,895,637 | 14,254,554 | 5,080,100 | 440,529 | 5,766,891 | 1,268,489 | 8,095,337 | 109,425,701 |
नकदी प्रवाह 17
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | · | · | $3.0K | $107.0K | $86.0K | |
| Stock-based Comp | $2M | $2M | $2M | $2M | $1M | $578.0K | $573.0K | $395.0K | $3M | $354.0K | $2M | $5M | |
| Deferred Tax | · | · | · | $0 | $-239.0K | $-22.0K | $-95.0K | $-1M | $39.0K | $-41.0K | $365.0K | $0 | |
| Amort. of Intangibles | · | · | · | · | · | · | · | $0 | $2M | · | · | $440.0K | |
| Other Non-cash | · | · | · | · | · | · | · | · | · | $-24M | · | · | |
| Operating Cash Flow | $-28M | $-35M | $-31M | $-24M | $-26M | $-10M | $-18M | $-30M | $-11M | $-12M | $-48M | $-43M | |
| CapEx | · | · | · | · | · | · | · | · | · | $6.0K | $153.0K | $57.0K | |
| Investing Cash Flow | · | $0 | $-6M | $-4M | $0 | · | · | $0 | $12M | $-85.0K | $10M | $-6M | |
| Debt Issued | · | · | · | · | · | · | · | · | · | $2M | $0 | $0 | |
| Net Debt Issued | · | · | · | · | · | · | $0 | · | · | $18M | · | · | |
| Stock Issued | · | $0 | $289.0K | $1M | $9M | $30M | $16M | $22M | $6M | $34M | $47M | $11M | |
| Net Stock Activity | · | $0 | $289.0K | $1M | $9M | $30M | $16M | · | $6M | $34M | · | · | |
| Dividends Paid | · | · | · | · | · | · | $0 | $487.0K | $0 | · | · | · | |
| Financing Cash Flow | $86M | $47M | $22M | $24M | $12M | $38M | $20M | $23M | $6M | $16M | $44M | $24M | |
| Net Change in Cash | $58M | $11M | $-15M | $-4M | $-14M | $28M | $2M | $-7M | $7M | $5M | $6M | $-24M | |
| Taxes Paid | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | $-45M | · | · |
लाभप्रदता 7
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | -4195.0% | -332.8% | -893.8% | · | · | 4986.8% | · | · | · | |
| Net Margin | · | · | · | -4130.1% | -272.4% | -881.9% | -16349.1% | · | 5141.6% | · | · | · | |
| Pretax Margin | · | · | · | -4130.1% | -275.5% | -882.8% | -16417.0% | · | 5086.8% | · | · | · | |
| EBITDA Margin | · | · | · | -4195.0% | -332.8% | -893.8% | · | · | 4986.8% | · | · | · | |
| ROA | -54.9% | -240.8% | -274.9% | -174.9% | -57.2% | -53.5% | -115.1% | · | -118.9% | -31.8% | · | · | |
| ROE | -55.4% | -243.6% | 632.7% | -473.4% | -88.2% | -93.3% | -340.3% | · | 1623.1% | -287.3% | · | · | |
| ROIC | -39.9% | -332.9% | 474.8% | -864.8% | -122.9% | -60.7% | · | · | -178.3% | -72.3% | · | · |
तरलता और शोधन क्षमता 4
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.7 | 1.7 | 0.2 | 1.1 | 4.6 | 3.0 | 1.6 | · | 0.5 | 1.2 | · | · | |
| Quick Ratio | 10.2 | 1.5 | 0.2 | 1.1 | 4.3 | 2.9 | 1.4 | · | 0.1 | 0.6 | · | · | |
| Debt / Equity | · | · | · | · | · | · | · | · | 5.3 | 0.6 | · | · | |
| LT Debt / Equity | · | · | · | · | · | · | · | · | 1.3 | · | · | · |
दक्षता 1
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | 0.0 | 0.0 | 0.2 | 0.1 | 0.0 | · | -0.0 | · | · | · |
विकास दरें 1
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | · | · | · | -86.8% | 300.0% | · | · | · | · | · | · | · |
मूल्यांकन (TTM) 17
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $0 | $0 | $0 | $1M | $8M | $2M | $0 | $10M | $10M | $10M | $10M | $9M | |
| Net Income TTM | $-27M | $-31M | $-37M | $-41M | $-21M | $-17M | $-19M | $-28M | $-24M | $-18M | $-64M | $-37M | |
| Market Cap | $577M | $77M | $34M | $50M | $88M | $83M | $22M | · | $2.25B | $44.20B | · | · | |
| Enterprise Value | · | · | · | · | · | · | · | · | $2.26B | $44.20B | · | · | |
| P/E | -15.1 | -2.1 | -0.8 | -1.1 | -4.1 | -2.8 | · | · | · | · | · | · | |
| P/S | · | · | · | 49.6 | 11.6 | 43.6 | · | · | 223.1 | 4384.0 | · | · | |
| P/B | 8.1 | 8.1 | -4.3 | 10.2 | 4.3 | 3.0 | 3.6 | · | 1086.5 | 1542.5 | · | · | |
| P / Tangible Book | 8.4 | 10.2 | · | 16.9 | 4.8 | 3.2 | · | · | · | · | · | · | |
| P / Cash Flow | -20.3 | -2.2 | -1.1 | -2.1 | -3.4 | -8.0 | -1.2 | · | -204.7 | -984.2 | · | · | |
| P / FCF | · | · | · | · | · | · | · | · | · | -984.0 | · | · | |
| EV / EBITDA | · | · | · | · | · | · | · | · | -98.0 | -1393.3 | · | · | |
| EV / FCF | · | · | · | · | · | · | · | · | · | -984.0 | · | · | |
| EV / Revenue | · | · | · | · | · | · | · | · | 223.9 | 4383.9 | · | · | |
| Dividend Yield | · | · | · | · | · | · | 0.00% | · | 0.00% | · | · | · | |
| Earnings Yield | -6.6% | -48.1% | -126.4% | -90.2% | -24.2% | -36.3% | · | · | · | · | · | · | |
| Payout Ratio | · | · | · | · | · | · | 0.00% | · | · | · | · | · | |
| Annual Payout | · | · | · | · | · | · | $0 | $487.0K | $0 | · | · | · |
आय विवरण 12
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| SG&A Expense | $4M | $4M | $4M | $3M | $3M | $3M | $2M | $3M | $2M | $5M | $3M | $4M | $3M | $4M | $4M | $3M | |
| Operating Expenses | $11M | $9M | $8M | $7M | $7M | $6M | $7M | $7M | $8M | $10M | $8M | $9M | $9M | $11M | $9M | $7M | |
| Operating Income | $-11M | $-9M | $-8M | $-7M | $-7M | $-6M | $-7M | $-7M | $-8M | $-10M | $-8M | $-9M | $-9M | $-11M | $-9M | $-7M | |
| Other Non-op | $1M | $845.0K | $597.0K | $292.0K | $272.0K | $250.0K | $181.0K | $221.0K | $151.0K | $79.0K | $41.0K | $94.0K | $210.0K | $184.0K | $325.0K | $124.0K | |
| Net Income | $-10M | $-8M | $-8M | $-7M | $-7M | $-6M | $-7M | $-7M | $-7M | $-10M | $-8M | $-9M | $-9M | $-11M | $-9M | $-7M | |
| EPS (Basic) | $-0.05 | $-0.05 | $-0.05 | $-0.06 | $-0.07 | $-0.07 | $-0.06 | $-0.10 | $-0.13 | $-0.21 | $-0.23 | $-0.33 | $-0.31 | $-0.47 | $-0.33 | $-0.34 | |
| EPS (Diluted) | $-0.05 | $-0.05 | $-0.05 | $-0.06 | $-0.07 | $-0.07 | $-0.06 | $-0.10 | $-0.13 | $-0.21 | $-0.23 | $-0.33 | $-0.31 | $-0.47 | $-0.33 | $-0.34 | |
| Shares (Basic) | 189,183,620 | 172,481,541 | -185,663,932 | 108,396,260 | 98,558,567 | 87,760,320 | -109,495,111 | 68,254,021 | 57,630,506 | 44,812,996 | -52,473,798 | 28,355,427 | 28,347,920 | 23,547,562 | -37,350,745 | 20,562,351 | |
| Shares (Diluted) | 189,183,620 | 172,481,541 | -185,663,932 | 108,396,260 | 98,558,567 | 87,760,320 | -109,495,111 | 68,254,021 | 57,630,506 | 44,812,996 | -52,473,798 | 28,355,427 | 28,347,920 | 23,547,562 | -37,350,745 | 20,562,351 | |
| EBITDA | $-11M | $-9M | · | $-7M | $-7M | $-6M | · | $-7M | $-8M | $-10M | · | $-9M | $-9M | $-11M | · | $-7M |
बैलेंस शीट 15
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $138M | $107M | $72M | $44M | $25M | $28M | $14M | $21M | $9M | $18M | $3M | $4M | $14M | $24M | $17M | $21M | |
| Prepaid Expense | $4M | $4M | $3M | $5M | $4M | $3M | $2M | $3M | $3M | $3M | $542.0K | $1M | $2M | $2M | $531.0K | $1M | |
| Current Assets | $143M | $111M | $75M | $49M | $29M | $32M | $16M | $24M | $12M | $22M | $3M | $5M | $16M | $26M | $18M | $23M | |
| Goodwill | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Total Assets | $145M | $114M | $78M | $52M | $32M | $35M | $19M | $27M | $15M | $24M | $6M | $8M | $19M | $29M | $21M | $26M | |
| Accounts Payable | $3M | $4M | $3M | $2M | $3M | $4M | $4M | $5M | $6M | $7M | $6M | $4M | $4M | $3M | $3M | $2M | |
| Accrued Liabilities | $4M | $2M | $4M | $3M | $2M | $3M | $5M | $5M | $5M | $7M | $8M | $7M | $6M | $6M | $6M | $5M | |
| Current Liabilities | $8M | $6M | $7M | $6M | $6M | $7M | $10M | $11M | $12M | $14M | $14M | $12M | $13M | $16M | $16M | $13M | |
| Capital Leases | $157.0K | $309.0K | $457.0K | $0 | $157.0K | $309.0K | $457.0K | $0 | $161.0K | $313.0K | $460.0K | $178.0K | $302.0K | $422.0K | $573.0K | $680.0K | |
| Total Liabilities | $8M | $7M | $7M | $6M | $6M | $7M | $10M | $11M | $12M | $15M | $14M | $12M | $14M | $16M | $16M | $13M | |
| Common Stock | $20.0K | $18.0K | $15.0K | $12.0K | $10.0K | $9.0K | $7.0K | $6.0K | $5.0K | $5.0K | $3.0K | $3.0K | $3.0K | $3.0K | $2.0K | $2.0K | |
| Retained Earnings | $-293M | $-283M | $-275M | $-267M | $-261M | $-254M | $-248M | $-241M | $-234M | $-227M | $-217M | $-209M | $-200M | $-191M | $-180M | $-171M | |
| Stockholders' Equity | $138M | $107M | $71M | $46M | $26M | $28M | $9M | $16M | $3M | $10M | $-8M | $-4M | $5M | $13M | $5M | $13M | |
| Liabilities + Equity | $145M | $114M | $78M | $52M | $32M | $35M | $19M | $27M | $15M | $24M | $6M | $8M | $19M | $29M | $21M | $26M | |
| Shares Outstanding | 201,918,874 | 181,332,574 | 153,103,459 | 125,078,525 | 100,367,113 | 90,896,125 | 73,977,459 | 64,381,979 | 57,754,928 | 56,267,670 | 32,132,890 | 28,393,958 | 28,347,920 | 28,347,920 | 21,005,405 | 20,588,247 |
नकदी प्रवाह 7
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $1M | $798.0K | $447.0K | $503.0K | $501.0K | $505.0K | $373.0K | $381.0K | $334.0K | $476.0K | $497.0K | $543.0K | $514.0K | $540.0K | $446.0K | $455.0K | |
| Operating Cash Flow | $-8M | $-9M | $-5M | $-7M | $-7M | $-9M | $-7M | $-8M | $-10M | $-11M | $-5M | $-7M | $-8M | $-12M | $-5M | $-6M | |
| Investing Cash Flow | · | · | · | · | · | · | · | $0 | · | · | $0 | $-3M | · | · | $0 | $0 | |
| Stock Issued | · | · | · | · | · | · | · | $0 | $0 | $0 | $21.0K | $0 | $0 | $268.0K | $929.0K | $69.0K | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | $0 | · | · | · | $268.0K | · | · | |
| Financing Cash Flow | $39M | $44M | $32M | $26M | $4M | $24M | $8.0K | $20M | $414.0K | $27M | $3M | $54.0K | $-29.0K | $19M | $929.0K | $107.0K | |
| Net Change in Cash | $31M | $35M | $27M | $19M | $-3M | $15M | $-7M | $12M | $-9M | $16M | $-1M | $-10M | $-10M | $7M | $-4M | $-6M |
लाभप्रदता 5
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | · | · | · | · | · | · | -12208.9% | · | · | · | · | · | · | |
| Net Margin | · | · | · | · | · | · | · | · | · | -12108.9% | · | · | · | · | · | · | |
| EBITDA Margin | · | · | · | · | · | · | · | · | · | -12208.9% | · | · | · | · | · | · | |
| ROA | -10.8% | -11.3% | · | -17.4% | -27.8% | -19.6% | · | -41.1% | -44.4% | -35.7% | · | -54.4% | -34.8% | -43.9% | · | -22.0% | |
| ROE | -11.7% | -12.4% | · | -22.1% | -45.4% | -31.1% | · | -117.8% | -192.6% | -83.7% | · | -211.3% | -74.0% | -129.1% | · | -35.8% |
तरलता और शोधन क्षमता 2
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 18.8 | 17.2 | · | 8.3 | 4.9 | 4.6 | · | 2.3 | 1.0 | 1.5 | · | 0.4 | 1.2 | 1.7 | · | 1.8 | |
| Quick Ratio | 18.3 | 16.6 | · | 7.5 | 4.2 | 4.1 | · | 2.0 | 0.8 | 1.3 | · | 0.3 | 1.0 | 1.5 | · | 1.7 |
दक्षता 1
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | · | · | · | · | · | · | · | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 |
मूल्यांकन (TTM) 9
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $0 | $0 | · | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | $0 | $1M | · | $1M | |
| Net Income TTM | $-31M | $-28M | · | $-26M | $-27M | $-30M | · | $-33M | $-35M | $-39M | · | $-36M | $-35M | $-43M | · | $-39M | |
| Market Cap | $2.98B | $767M | · | $201M | $220M | $98M | · | $80M | $69M | $57M | · | $47M | $45M | $41M | · | $42M | |
| P/E | -64.2 | -16.9 | · | -5.4 | -5.9 | -2.1 | · | -1.6 | -1.2 | -0.8 | · | -1.1 | -1.0 | -0.6 | · | -0.9 | |
| P/S | · | · | · | · | · | · | · | · | · | · | · | · | · | 40.5 | · | 41.6 | |
| P/B | 21.7 | 7.1 | · | 4.4 | 8.4 | 3.5 | · | 5.1 | 23.6 | 5.9 | · | -12.2 | 9.2 | 3.1 | · | 3.3 | |
| P / Tangible Book | 22.0 | 7.3 | · | 4.6 | 9.1 | 3.8 | · | 5.8 | 68.8 | 7.3 | · | · | 15.2 | 3.6 | · | 3.9 | |
| P / Cash Flow | · | -86.7 | · | · | · | -10.8 | · | · | · | -5.3 | · | · | · | -3.3 | · | · | |
| Earnings Yield | -1.6% | -5.9% | · | -18.6% | -16.9% | -47.2% | · | -61.6% | -82.3% | -130.7% | · | -88.4% | -97.5% | -158.7% | · | -111.4% |
वित्तीय विवरण आय विवरण, बैलेंस शीट, नकदी प्रवाह — वार्षिक, पिछले 5 वर्ष
आय विवरण
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| राजस्व | — | — | $0 | $1M | $8M |
| परिचालन मार्जिन % | — | — | — | -4195.0% | -332.8% |
| शुद्ध आय | $-27M | $-31M | $-37M | $-41M | $-21M |
| तनुकरणित EPS | $-0.25 | $-0.50 | $-1.34 | $-2.13 | $-1.34 |
बैलेंस शीट
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| वर्तमान अनुपात | 10.7 | 1.7 | 0.2 | 1.1 | 4.6 |
| त्वरित अनुपात | 10.2 | 1.5 | 0.2 | 1.1 | 4.3 |
ताज़ा समाचार इस कंपनी का उल्लेख करने वाली हालिया सुर्खियां
मेरे मेट्रिक्स आपकी व्यक्तिगत वॉचलिस्ट — पूर्ण फंडामेंटल से चयनित पंक्तियाँ
उन मेट्रिक्स को चुनें जो आपके लिए मायने रखते हैं — ऊपर पूर्ण फंडामेंटल में किसी भी पंक्ति के बगल में ➕ पर क्लिक करें।
आपका चयन सहेजा गया है और यह सभी टिकर में आपके साथ रहता है।
संस्थागत मालिक (13F) 232 फाइलर्स · $1.2B कुल · तिथि अनुसार 30 जून 2026
संस्थान जो अपनी तिमाही SEC फॉर्म 13F में इस स्टॉक को होल्ड करने की रिपोर्ट करते हैं। केवल लॉन्ग पोजीशन; एक ही फाइलर अलग-अलग ऑप्शन लेग्स के लिए दो बार दिखाई दे सकता है। बड़े ऑफसेटिंग पुट/कॉल लेग्स आमतौर पर मार्केट-मेकिंग या हेज्ड इन्वेंट्री को दर्शाते हैं, न कि दिशात्मक विश्वास को।
| नई स्थितियाँ | बाहर निकली पोजीशन | बढ़ाया | घटा हुआ | शुद्ध शेयर परिवर्तन |
|---|---|---|---|---|
| 88 (+21 पिछली तिमाही की तुलना में) | 19 (+4 पिछली तिमाही की तुलना में) | 70 (+12 पिछली तिमाही की तुलना में) | 38 (+15 पिछली तिमाही की तुलना में) | +29.5M |
Q1 2026 की तुलना में। SEC फॉर्म 13F फाइलिंग तिमाही के अंत के 45 दिनों के भीतर देय होती है, साथ ही देर से फाइल करने वालों के लिए एक छोटा बफर भी होता है — उस विंडो के भीतर आने वाली तिमाहियों को सबसे हालिया पूरी तरह से रिपोर्ट की गई जोड़ी के पक्ष में छोड़ दिया जाता है।
| संस्था | मूल्य | शेयर | % ट्रैक किए गए 13F का | प्रकार |
|---|---|---|---|---|
| STATE STREET CORP | $191829196 | 12996558 | 15.97% | शेयर |
| VANGUARD CAPITAL MANAGEMENT LLC | $121417310 | 8226105 | 10.11% | शेयर |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $105640272 | 7157200 | 8.79% | कॉल ऑप्शन |
| Anson Funds Management LP | $66420000 | 4500000 | 5.53% | शेयर |
| CITADEL ADVISORS LLC | $64157292 | 4346700 | 5.34% | कॉल ऑप्शन |
| GEODE CAPITAL MANAGEMENT, LLC | $61905400 | 4193009 | 5.15% | शेयर |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $61832592 | 4189200 | 5.15% | पुट ऑप्शन |
| CITADEL ADVISORS LLC | $33333984 | 2258400 | 2.77% | पुट ऑप्शन |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $31897821 | 2161099 | 2.66% | शेयर |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $30266812 | 2050597 | 2.52% | शेयर |
| JONES FINANCIAL COMPANIES LLLP | $28553511 | 2304561 | 2.38% | शेयर |
| VANGUARD GROUP INC | $27868421 | 7392154 | 2.32% | शेयर |
| Anson Funds Management LP | $27245484 | 1845900 | 2.27% | पुट ऑप्शन |
| PERCEPTIVE ADVISORS LLC | $22140000 | 1500000 | 1.84% | पुट ऑप्शन |
| VANGUARD FIDUCIARY TRUST CO | $19707050 | 1335166 | 1.64% | शेयर |
| Sio Capital Management, LLC | $18165132 | 1230700 | 1.51% | पुट ऑप्शन |
| BNP PARIBAS FINANCIAL MARKETS | $15823045 | 1072022 | 1.32% | शेयर |
| MILLENNIUM MANAGEMENT LLC | $13372560 | 906000 | 1.11% | पुट ऑप्शन |
| BARCLAYS PLC | $11831616 | 801600 | 0.98% | पुट ऑप्शन |
| Anson Funds Management LP | $11808000 | 800000 | 0.98% | कॉल ऑप्शन |
| BNP PARIBAS FINANCIAL MARKETS | $11734200 | 7950 | 0.98% | पुट ऑप्शन |
| JANE STREET GROUP, LLC | $11058192 | 749200 | 0.92% | कॉल ऑप्शन |
| MORGAN STANLEY | $9922380 | 672248 | 0.83% | शेयर |
| BANK OF AMERICA CORP /DE/ | $9150359 | 619943 | 0.76% | शेयर |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $8339518 | 565008 | 0.69% | शेयर |
| JANE STREET GROUP, LLC | $7462700 | 505603 | 0.62% | शेयर |
| Balyasny Asset Management L.P. | $7380000 | 500000 | 0.61% | पुट ऑप्शन |
| LMR Partners LLP | $6642000 | 450000 | 0.55% | पुट ऑप्शन |
| NOMURA HOLDINGS INC | $6273000 | 425000 | 0.52% | कॉल ऑप्शन |
| DIADEMA PARTNERS LP | $5904000 | 400000 | 0.49% | कॉल ऑप्शन |
| Swiss National Bank | $5319504 | 360400 | 0.44% | शेयर |
| XTX Topco Ltd | $5300168 | 359090 | 0.44% | शेयर |
| Ikarian Capital, LLC | $5235372 | 354700 | 0.44% | पुट ऑप्शन |
| CITIGROUP INC | $4659717 | 315699 | 0.39% | शेयर |
| RENAISSANCE TECHNOLOGIES LLC | $4580973 | 310364 | 0.38% | शेयर |
| DAGCO, INC. | $4351740 | 1028780 | 0.36% | शेयर |
| Everhart Financial Group, Inc. | $4251146 | 288018 | 0.35% | शेयर |
| Rafferty Asset Management, LLC | $3540806 | 239892 | 0.29% | शेयर |
| RHUMBLINE ADVISERS | $3400726 | 230402 | 0.28% | शेयर |
| Walleye Capital LLC | $3377088 | 228800 | 0.28% | पुट ऑप्शन |
| GOLDMAN SACHS GROUP INC | $3125991 | 211788 | 0.26% | शेयर |
| TUDOR INVESTMENT CORP ET AL | $3087792 | 209200 | 0.26% | पुट ऑप्शन |
| WELLINGTON MANAGEMENT GROUP LLP | $2992738 | 202760 | 0.25% | शेयर |
| BOOTHBAY FUND MANAGEMENT, LLC | $2982996 | 202100 | 0.25% | पुट ऑप्शन |
| Jefferies Financial Group Inc. | $2958775 | 200459 | 0.25% | शेयर |
| Jefferies Financial Group Inc. | $2953476 | 200100 | 0.25% | पुट ऑप्शन |
| Mariner, LLC | $2925609 | 198212 | 0.24% | शेयर |
| MILLENNIUM MANAGEMENT LLC | $2895912 | 196200 | 0.24% | कॉल ऑप्शन |
| Bank of New York Mellon Corp | $2801212 | 189784 | 0.23% | शेयर |
| ALPS ADVISORS INC | $2776459 | 188107 | 0.23% | शेयर |
| JANE STREET GROUP, LLC | $2405880 | 163000 | 0.20% | पुट ऑप्शन |
| LPL Financial LLC | $2297586 | 155663 | 0.19% | शेयर |
| SIMPLEX TRADING, LLC | $2274501 | 154099 | 0.19% | शेयर |
| BlackRock, Inc. | $2222708 | 150590 | 0.19% | शेयर |
| WELLS FARGO & COMPANY/MN | $2208775 | 149646 | 0.18% | शेयर |
| Vontobel Holding Ltd. | $2166207 | 146762 | 0.18% | शेयर |
| TUDOR INVESTMENT CORP ET AL | $2069352 | 140200 | 0.17% | कॉल ऑप्शन |
| Vanguard Global Advisers, LLC | $1918874 | 130005 | 0.16% | शेयर |
| VANGUARD ASSET MANAGEMENT, Ltd | $1859598 | 125989 | 0.15% | शेयर |
| Caption Management, LLC | $1845000 | 125000 | 0.15% | पुट ऑप्शन |
| PROFUND ADVISORS LLC | $1780159 | 120607 | 0.15% | शेयर |
| MetLife Investment Management, LLC | $1624810 | 110082 | 0.14% | शेयर |
| Daiwa Securities Group Inc. | $1589652 | 107700 | 0.13% | पुट ऑप्शन |
| Daiwa Securities Group Inc. | $1512900 | 102500 | 0.13% | शेयर |
| DIADEMA PARTNERS LP | $1476000 | 100000 | 0.12% | पुट ऑप्शन |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | $1467144 | 99400 | 0.12% | शेयर |
| STATE OF WISCONSIN INVESTMENT BOARD | $1405300 | 95210 | 0.12% | शेयर |
| Harvest Investment Services, LLC | $1394554 | 94482 | 0.12% | शेयर |
| ORBIMED ADVISORS LLC | $1365300 | 92500 | 0.11% | पुट ऑप्शन |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $1229582 | 83305 | 0.10% | शेयर |
| Invesco Ltd. | $1104816 | 74852 | 0.09% | शेयर |
| Gotham Asset Management, LLC | $1097317 | 74344 | 0.09% | शेयर |
| FULCRUM WEALTH ADVISORS, LLC | $1081214 | 73253 | 0.09% | शेयर |
| ALLIANCEBERNSTEIN L.P. | $998534 | 236060 | 0.08% | शेयर |
| NEW YORK STATE COMMON RETIREMENT FUND | $978588 | 66300 | 0.08% | शेयर |
| Verition Fund Management LLC | $916596 | 62100 | 0.08% | पुट ऑप्शन |
| OSAIC HOLDINGS, INC. | $889776 | 60284 | 0.07% | शेयर |
| FIFTH THIRD BANCORP | $888404 | 60190 | 0.07% | शेयर |
| State of New Jersey Common Pension Fund D | $857069 | 58067 | 0.07% | शेयर |
| Verition Fund Management LLC | $832464 | 56400 | 0.07% | कॉल ऑप्शन |
| Police & Firemen's Retirement System of New Jersey | $821630 | 55666 | 0.07% | शेयर |
| ARIZONA STATE RETIREMENT SYSTEM | $731388 | 49552 | 0.06% | शेयर |
| Caption Management, LLC | $728745 | 49373 | 0.06% | शेयर |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $722310 | 48937 | 0.06% | शेयर |
| Russell Investments Group, Ltd. | $704494 | 47730 | 0.06% | शेयर |
| SIG BROKERAGE, LP | $689292 | 46700 | 0.06% | कॉल ऑप्शन |
| Vanguard Investments Australia, Ltd. | $684643 | 46385 | 0.06% | शेयर |
| COMMONWEALTH EQUITY SERVICES, LLC | $665481 | 45087 | 0.06% | शेयर |
| INSTRUMENTAL WEALTH, LLC | $662931 | 44914 | 0.06% | शेयर |
| Persistent Asset Partners Ltd | $655647 | 758 | 0.05% | कॉल ऑप्शन |
| Virtus Investment Advisers, LLC | $616791 | 41788 | 0.05% | शेयर |
| Accurate Wealth Management, LLC | $614707 | 47462 | 0.05% | शेयर |
| AXXCESS WEALTH MANAGEMENT, LLC | $610665 | 41373 | 0.05% | शेयर |
| KLP KAPITALFORVALTNING AS | $600732 | 40700 | 0.05% | शेयर |
| SJS Investment Consulting Inc. | $590400 | 40000 | 0.05% | शेयर |
| Wealthfront Advisers LLC | $587773 | 39822 | 0.05% | शेयर |
| Quantinno Capital Management LP | $546651 | 37036 | 0.05% | शेयर |
| Visionary Horizons, LLC | $531360 | 36000 | 0.04% | शेयर |
| Kestra Advisory Services, LLC | $516305 | 34980 | 0.04% | शेयर |
| NORTHSTAR ASSET MANAGEMENT Co | $509400 | 45000 | 0.04% | शेयर |
कंपनी के अंदरूनी सूत्र 42 इनसाइडर्स · 17 अधिकारी · 9 निदेशक
| अंदरूनी | भूमिका | अंतिम गतिविधि | शेयरों का स्वामित्व | खरीद 12m | बिक्री 12m | नेट 12m |
|---|---|---|---|---|---|---|
| Andelos M. Stergiou | President and CEO | 16 जून 2026 A | 1759183 | 0 | 0 | $0 |
| Noah D Beerman | CEO and President | 15 मार्च 2011 A | 92994 | 0 | 0 | $0 |
| John Thomas Burns | CFO | 7 जनवरी 2026 A | 554327 | 0 | 0 | $0 |
| Gene Mack | CFO and Treasurer | 20 अप्रैल 2018 A | — | 0 | 0 | $0 |
| Robert Eugene Kennedy | Vice President and CFO | 13 अप्रैल 2011 A | 379294 | 0 | 0 | $0 |
| Stephen J. Dipalma | CFO, EVP, Secretary | 15 जनवरी 2009 A | — | 0 | 0 | $0 |
| Dragan Cicic | SVP, Chief Development Officer | 7 जनवरी 2026 A | 557805 | 0 | 0 | $0 |
| Robert Francomano | Chief Commercial Officer | 22 जनवरी 2024 A | 40918 | 0 | 0 | $0 |
| Barbara A Wood | EVP, Gen. Counsel, Corp. Sec. | 22 जनवरी 2024 A | 117225 | 0 | 0 | $0 |
| Nicholas J. Sarlis | Chief Medical Officer and SVP | 14 मार्च 2019 A | — | 0 | 0 | $0 |
| Gregory M Torre | CRO and SVP | 13 मार्च 2018 A | — | 0 | 0 | $0 |
| Amy B Tata | Principlw Acctg Officer & Cont | 15 मार्च 2011 A | 14065 | 0 | 0 | $0 |
| Ramani Varanasi | VP Business Development | 15 मार्च 2011 A | 41083 | 0 | 0 | $0 |
| Anastasia Khvorova | Chief Science Officer | 15 मार्च 2011 A | 60559 | 0 | 0 | $0 |
| Pamela Pavco | VP of Pharmaceutical Devlpmt | 15 मार्च 2011 A | 44940 | 0 | 0 | $0 |
| Konstantinos Andrikopoulos | VP, Legal | 15 अप्रैल 2010 A | 5750 | 0 | 0 | $0 |
| Dmitry Samarsky | VP, Technology Development | 31 मार्च 2010 S | 0 | 0 | 0 | $0 |
| Katherine Bach Kalin | निदेशक | 7 जनवरी 2026 A | 154400 | 1 | 0 | $100806 |
| John Varian | निदेशक | 7 जनवरी 2026 A | 72900 | 0 | 0 | $0 |
| Jane Wasman | निदेशक | 7 जनवरी 2026 A | 92900 | 0 | 0 | $0 |
| David A Scheinberg | निदेशक | 7 जनवरी 2026 A | 73082 | 0 | 0 | $0 |
| Robert L Van Nostrand | निदेशक | 7 जनवरी 2026 A | 82900 | 0 | 0 | $0 |
| Stephen F Ghiglieri | निदेशक | 14 मार्च 2019 A | — | 0 | 0 | $0 |
| Fabio Lopez | निदेशक | 12 जून 2018 A | — | 0 | 0 | $0 |
| Irving M. Einhorn | — | 10 अक्टूबर 2017 A | 34690 | 0 | 0 | $0 |
| William Ashton | — | 10 अक्टूबर 2017 A | 38154 | 0 | 0 | $0 |
| Richard Chin | — | 10 अक्टूबर 2017 A | 31339 | 0 | 0 | $0 |
| Rudolph Nisi | — | 10 अक्टूबर 2017 A | 42918 | 0 | 0 | $0 |
| Sanford Hillsberg | — | 10 अक्टूबर 2017 A | 56950 | 0 | 0 | $0 |
| Mary Ann Gray | — | 10 अक्टूबर 2017 A | 39167 | 0 | 0 | $0 |
| Stephen S Galliker | — | 10 अक्टूबर 2017 A | 36039 | 0 | 0 | $0 |
| Thomas J Knapp | — | 6 फ़रवरी 2017 A | — | 0 | 0 | $0 |
| Bijan Nejadnik | — | 17 जनवरी 2017 A | — | 0 | 0 | $0 |
| Ryan Dunlap | — | 1 जून 2016 M | 18702 | 0 | 0 | $0 |
| Mark W. Schwartz | — | 18 दिसमबर 2015 A | 415972 | 0 | 0 | $0 |
| Steven A Kriegsman | — | 19 जून 2015 A | 5000 | 0 | 0 | $0 |
| Margaret Kivinski | — | 16 जनवरी 2015 A | — | 0 | 0 | $0 |
| Brian L Hamilton | — | 30 जून 2014 J | 2461 | 0 | 0 | $0 |
| Mark J Ahn | — | 30 जून 2014 A | 116225 | 0 | 0 | $0 |
| Rosemary Mazanet | — | 29 जनवरी 2013 A | — | 0 | 0 | $0 |
| CYTRX CORP | — | 29 दिसमबर 2010 S | 0 | 0 | 0 | $0 |
| Tod Woolf | — | 15 जनवरी 2009 A | — | 0 | 0 | $0 |
SEC फॉर्म 3/4/5 फाइलिंग से अंदरूनी सूत्र; नेट = केवल ओपन-मार्केट P/S
कार्यकर्ता और 5%+ मालिक 2 होल्डिंग्स
जिन निवेशकों ने SEC शेड्यूल 13D दाखिल किया है — जारीकर्ता को प्रभावित करने के इरादे से 5% से अधिक लाभकारी स्वामित्व (कार्यकर्ता दांव, बोर्ड अभियान, M&A)। प्रत्येक पंक्ति उस फाइलर की स्थिति की सबसे हालिया ज्ञात स्थिति दिखाती है।
| फाइलर | दाखिल किया | दांव | स्थिति | उद्देश्य | फाइलिंग |
|---|---|---|---|---|---|
| Equilibria Capital Management Limited (2), EQC Private Markets SAC Fund II Ltd — EQC Biotech Sely S Fund (2), EQC Private Markets SAC Fund Ltd — EQC Biotech Sely I Fund (2), EQC Private Markets SAC Fund Ltd — EQC Biotech Sely II Fund (2), EQC Private Markets II SAC Fund Ltd — EQC Biotech Sely III Fund (2), Varibobi Financial Holdings Ltd. (2), Daniel Tafur (2), Fabio López (2) ×4 फाइलिंग | 10 अक्टूबर 2018 | — | प्रारंभिक फाइलिंग | — | SEC |
| Angelos M. Stergiou, M.D., Sc.D. h.c. | 8 जनवरी 2018 | — | प्रारंभिक फाइलिंग | M&A / बिक्री | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ईटीएफ स्वामित्व 29 ETFs द्वारा धारित
वजन केवल प्रत्यक्ष इक्विटी होल्डिंग्स (N-PORT) को दर्शाता है; लीवरेज्ड या डेरिवेटिव-आधारित फंड में अतिरिक्त स्वैप एक्सपोजर हो सकता है जो नहीं दिखाया गया है।
| फंड | भार | इकाइयाँ | तिथि अनुसार | स्रोत |
|---|---|---|---|---|
| LABU · Direxion Shares ETF Trust | 0.26% | 268465 NS | 30 अप्रैल 2026 | N-PORT |
| CANC · Tema ETF Trust | 0.22% | 40702 NS | 31 मई 2026 | N-PORT |
| GSSC · Goldman Sachs ETF Trust | 0.05% | 51293 NS | 31 मई 2026 | N-PORT |
| ITWO · ProShares Trust | 0.04% | 8088 NS | 31 मई 2026 | N-PORT |
| RSSL · Global X Funds | 0.03% | 74459 NS | 30 अप्रैल 2026 | N-PORT |
| UWM · ProShares Trust | 0.02% | 6326 NS | 31 मई 2026 | N-PORT |
| URTY · ProShares Trust | 0.02% | 6397 NS | 31 मई 2026 | N-PORT |
| HDG · ProShares Trust | 0.01% | 161 NS | 31 मई 2026 | N-PORT |
| ONEQ · Fidelity Commonwealth Trust | 0.01% | 64480 NS | 31 मई 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0.00% | 3554 NS | 31 मई 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | — | — | 15 जुलाई 2026 | दैनिक |
| VTI · VANGUARD INDEX FUNDS | — | — | 15 जुलाई 2026 | दैनिक |
| VFMO · VANGUARD WELLINGTON FUND | — | — | 30 जुलाई 2026 | दैनिक |
| VTWO · VANGUARD SCOTTSDALE FUNDS | — | — | 15 जुलाई 2026 | दैनिक |
| VTWG · VANGUARD SCOTTSDALE FUNDS | — | — | 15 जुलाई 2026 | दैनिक |
| VTHR · VANGUARD SCOTTSDALE FUNDS | — | — | 15 जुलाई 2026 | दैनिक |
| ITOT · iShares Trust | — | — | 22 जुलाई 2026 | दैनिक |
| IWV · iShares Trust | — | — | 18 अगस्त 2026 | दैनिक |
| IWO · iShares Trust | — | — | 18 अगस्त 2026 | दैनिक |
| IWM · iShares Trust | — | — | 18 अगस्त 2026 | दैनिक |
| IWC · iShares Trust | — | — | 18 अगस्त 2026 | दैनिक |
| ICOP · iShares Trust | — | — | 18 अगस्त 2026 | दैनिक |
| VHT · VANGUARD WORLD FUND | — | — | 20 जुलाई 2026 | दैनिक |
| PICK · iShares, Inc. | — | — | 14 अगस्त 2026 | दैनिक |
| ISCB · iShares Trust | — | — | 21 जुलाई 2026 | दैनिक |
| ISCG · iShares Trust | — | — | 21 जुलाई 2026 | दैनिक |
| ISCF · iShares Trust | — | — | 10 अगस्त 2026 | दैनिक |
| WSML · iShares Trust | — | — | 10 अगस्त 2026 | दैनिक |
| DWAS · Invesco Exchange-Traded Fund Trust … | — | — | 20 जुलाई 2026 | दैनिक |